MALDI mass spectrometry imaging unravels organ and amyloid-type specific peptide signatures in pulmonary and gastrointestinal amyloidosis
- PMID: 34061454
- DOI: 10.1002/prca.202000079
MALDI mass spectrometry imaging unravels organ and amyloid-type specific peptide signatures in pulmonary and gastrointestinal amyloidosis
Abstract
Purpose: Amyloidosis is a disease group caused by pathological aggregation and deposition of peptides in diverse tissue sites. Recently, matrix-assisted laser desorption/ionization mass spectrometry imaging coupled with ion mobility separation (MALDI-IMS MSI) was introduced as a novel tool to identify and classify amyloidosis using single sections from formalin-fixed and paraffin-embedded cardiac biopsies. Here, we tested the hypothesis that MALDI-IMS MSI can be applied to lung and gastrointestinal specimens.
Experimental design: Forty six lung and 65 gastrointestinal biopsy and resection specimens with different types of amyloid were subjected to MALDI-IMS MSI. Ninety three specimens included tissue areas without amyloid as internal negative controls. Nine cases without amyloid served as additional negative controls.
Results: Utilizing a peptide filter method and 21 known amyloid specific tryptic peptides we confirmed the applicability of a universal peptide signature with a sensitivity of 100% and a specificity of 100% for the detection of amyloid deposits in the lung and gastrointestinal tract. Additionally, the frequencies of individual m/z-values of the 21 tryptic marker peptides showed organ- and tissue-type specific differences.
Conclusions and clinical relevance: MALDI-IMS MSI adds a valuable analytical approach to diagnose and classify amyloid and the detection frequency of individual tryptic peptides is organ-/tissue-type specific.
Keywords: MALDI-IMS MS imaging; amyloidosis; formalin-fixed and paraffin-embedded; ion mobility separation.
© 2021 The Authors. Proteomics - Clinical Applications published by Wiley-VCH GmbH.
Similar articles
-
Topologies of amyloidogenic proteins in Congo red-positive sliced sections of formalin-fixed paraffin embedded tissues by MALDI-MS imaging coupled with on-tissue tryptic digestion.Clin Biochem. 2013 Oct;46(15):1595-600. doi: 10.1016/j.clinbiochem.2013.05.063. Epub 2013 May 31. Clin Biochem. 2013. PMID: 23732480
-
Imaging mass spectrometry analysis of renal amyloidosis biopsies reveals protein co-localization with amyloid deposits.Anal Bioanal Chem. 2015 Jul;407(18):5323-31. doi: 10.1007/s00216-015-8689-z. Epub 2015 May 3. Anal Bioanal Chem. 2015. PMID: 25935672
-
MALDI Mass Spectrometry Imaging: A Novel Tool for the Identification and Classification of Amyloidosis.Proteomics. 2017 Nov;17(22):1700236. doi: 10.1002/pmic.201700236. Proteomics. 2017. PMID: 28994248 Free PMC article.
-
[Amyloid Registry Kiel : An interim balance].Pathologe. 2018 Dec;39(Suppl 2):301-305. doi: 10.1007/s00292-018-0515-x. Pathologe. 2018. PMID: 30302563 Review. German.
-
Pathology and diagnosis of renal non-AL amyloidosis.J Nephrol. 2018 Jun;31(3):343-350. doi: 10.1007/s40620-017-0426-6. Epub 2017 Aug 21. J Nephrol. 2018. PMID: 28828707 Review.
Cited by
-
Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics.Medicina (Kaunas). 2021 Aug 31;57(9):916. doi: 10.3390/medicina57090916. Medicina (Kaunas). 2021. PMID: 34577839 Free PMC article. Review.
-
Amyloidosis: What does pathology offer? The evolving field of tissue biopsy.Front Cardiovasc Med. 2022 Dec 5;9:1081098. doi: 10.3389/fcvm.2022.1081098. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36545023 Free PMC article. Review.
-
N-terminal peptide fragment constitutes core of amyloid deposition of serum amyloid A: An imaging mass spectrometry study.PLoS One. 2022 Oct 14;17(10):e0275993. doi: 10.1371/journal.pone.0275993. eCollection 2022. PLoS One. 2022. PMID: 36240260 Free PMC article.
-
Prospective on Imaging Mass Spectrometry in Clinical Diagnostics.Mol Cell Proteomics. 2023 Sep;22(9):100576. doi: 10.1016/j.mcpro.2023.100576. Epub 2023 May 19. Mol Cell Proteomics. 2023. PMID: 37209813 Free PMC article. Review.
References
REFERENCES
-
- Benson, M. D., Buxbaum, J. N., Eisenberg, D. S., Merlini, G., Saraiva, M. J. M., Sekijima, Y., Sipe, J. D., & Westermark, P. (2020). Amyloid nomenclature 2020: Update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid, 27(4), 217-222. https://doi.org/10.1080/13506129.2020.1835263
-
- Chiti, F., & Dobson, C. M. (2017). Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade. Annual Review of Biochemistry, 86, 27-68. https://doi.org/10.1146/annurev-biochem-061516-045115
-
- Buxbaum, J. N. (2019). Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: The role of randomized controlled trials. Amyloid, 26(2), 55-65. https://doi.org/10.1080/13506129.2019.1575201
-
- Gertz, M. A. (2020). Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. American Journal of Hematology, 95(7), 848-860. https://doi.org/10.1002/ajh.25819
-
- Mahmood, S., Bridoux, F., Venner, C. P., Sachchithanantham, S., Gilbertson, J. A., Rowczenio, D., Wagner, T., Sayed, R., Patel, K., Fontana, M., Whelan, C. J., Lachmann, H. J., Hawkins, P. N., Gillmore, J. D., & Wechalekar, A. D. (2015). Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: A long-term observational study. The Lancet Haematology, 2(6), e241-e250. https://doi.org/10.1016/S2352-3026(15)00068-X
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical